Sovereign Pharmaceuticals, LLC

Alcon, Inc.

Alcon Research, Ltd.

Taro Pharmaceuticals North America, Inc.

Taro Pharmaceutical North America, Inc.

Rao, Srinivasa

Suresh Dixit

Onkar N Singh

Ralph T Brown

Juan Carlos Menendez

Wesley Wehsin Han

Avraham Yacobi

Ernesto J Castillo

Haresh G Bhagat

Huixiang Zhang

Joseph Paul Bullock

Arthur Bailey

Michael Wall

Srinivasa Rao

A combination of dosage units for alleviating respiratory ailments and a method of alleviating respiratory ailments which uses this combination of dosage units. The dosage units comprise one or more first dosage units comprising pseudoephedrine and/or a pharmaceutically acceptable salt thereof and one or more second dosage units comprising phenylephrine and/or a pharmaceutically acceptable salt thereof.

Alternating sympathomimetic therapy for the treatment of respiratory ailments

The present invention relates to a stable liquid formulation comprising desoximetasone, isopropyl myristate, a C-Calcohol and a stabilizing agent. Specifically, the present invention provides a liquid formulation comprising: a) about 0.01 wt % to about 2.5 wt % desoximetasone; b) about 10 wt % to about 70 wt % isopropyl myristate; c) about 20 wt % to about 70 wt % C-Calcohol; and d) a stabilizing agent selected from the group consisting of an oleaginous vehicle and a propellant, wherein the stabilizing agent is in an amount sufficient to reduce the formation of less than about 1 wt % 17-carboxy-9&#x3b1;-fluoro-11&#x3b2;-hydroxy-16&#x3b1;-methyl-androsta-1,4-diene-3-one under an accelerated storage condition.

Stable liquid desoximethasone compositions with reduced oxidized impurity

A combination of dosage units for alleviating respiratory ailments and a method of alleviating respiratory ailments which uses this combination of dosage units. The dosage units comprise one or more first dosage units comprising pseudoephedrine and/or a pharmaceutically acceptable salt thereof and one or more second dosage units comprising phenylephrine and/or a pharmaceutically acceptable salt thereof. This Abstract is neither intended to define the invention disclosed in this specification nor intended to limit the scope of the invention in any way.

Alternating sympathomimetic therapy for the treatment of respiratory aliments

The present invention relates to a stable liquid formulation comprising desoximetasone, isopropyl myristate, a C-Calcohol and a stabilizing agent. Specifically, the present invention provides a liquid formulation comprising: a) about 0.01 wt % to about 2.5 wt % desoximetasone; b) about 10 wt % to about 70 wt % isopropyl myristate; c) about 20 wt % to about 70 wt % C-Calcohol; and d) a stabilizing agent selected from the group consisting of an oleaginous vehicle and a propellant, wherein the stabilizing agent is in an amount sufficient to reduce the formation of less than about 1 wt % 17-carboxy-9&#x3b1;-fluoro-11&#x3b2;-hydroxy-16a-methyl-androsta-1,4-diene-3-one under an accelerated storage condition.

Topical ophthalmic and otic solution compositions of moxifloxacin and dexamethasone phosphate are disclosed.

Topical ophthalmic or otic solution formulations containing moxifloxacin hydrochloride and dexamethasone phosphate

Topical formulations of olopatadine for treatment of allergic or inflammatory disorders of the eye and nose are disclosed. The aqueous formulations contain approximately 0.17-0.62% (w/v) of olopatadine and an amount of polyvinylpyrrolidone or polystyrene sulfonic acid sufficient to enhance the physical stability of the formulations.

Olopatadine formulations for topical administration

Growing community of inventors

Fort Worth, TX, United States of America

Suresh Dixit